ATE394676T1 - Verbindungen und verfahren zur diagnose von prostatakrebs - Google Patents

Verbindungen und verfahren zur diagnose von prostatakrebs

Info

Publication number
ATE394676T1
ATE394676T1 AT04720550T AT04720550T ATE394676T1 AT E394676 T1 ATE394676 T1 AT E394676T1 AT 04720550 T AT04720550 T AT 04720550T AT 04720550 T AT04720550 T AT 04720550T AT E394676 T1 ATE394676 T1 AT E394676T1
Authority
AT
Austria
Prior art keywords
prostate cancer
compounds
methods
diagnosing prostate
diagnosing
Prior art date
Application number
AT04720550T
Other languages
English (en)
Inventor
Nathan Karin
Original Assignee
Rappaport Family Inst For Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Inst For Res filed Critical Rappaport Family Inst For Res
Application granted granted Critical
Publication of ATE394676T1 publication Critical patent/ATE394676T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT04720550T 2003-03-12 2004-03-14 Verbindungen und verfahren zur diagnose von prostatakrebs ATE394676T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45351503P 2003-03-12 2003-03-12
US45351403P 2003-03-12 2003-03-12
US52513503P 2003-11-28 2003-11-28
US53411104P 2004-01-05 2004-01-05

Publications (1)

Publication Number Publication Date
ATE394676T1 true ATE394676T1 (de) 2008-05-15

Family

ID=32996377

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720550T ATE394676T1 (de) 2003-03-12 2004-03-14 Verbindungen und verfahren zur diagnose von prostatakrebs

Country Status (5)

Country Link
US (2) US7749714B2 (de)
EP (1) EP1601682B1 (de)
AT (1) ATE394676T1 (de)
DE (1) DE602004013554D1 (de)
WO (1) WO2004080273A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080273A2 (en) 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating prostate cancer
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
MX2008002101A (es) 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
WO2007100920A2 (en) * 2006-03-01 2007-09-07 The Regents Of The University Of Michigan Diagnosis and treatment of prostate cancer
US20090202513A1 (en) * 2008-01-07 2009-08-13 The University Of Vermont And State Agriculture College Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
US20140199292A1 (en) * 2011-03-15 2014-07-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence
KR20150091504A (ko) * 2012-12-07 2015-08-11 백스터 인터내셔널 인코포레이티드 항―ｍｉｆ 항체 세포 이동 검정법
EP3529617B1 (de) * 2016-10-24 2023-05-17 Roche Diagnostics GmbH Immobilisierte analyte

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5529898A (en) 1993-08-19 1996-06-25 Duke University Methods of detecting disorders of the central nervous system by detecting autoantibodies which specifically bind ionotropic glutamate receptors
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5459128A (en) 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US6429289B1 (en) 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US7245748B2 (en) * 1997-01-21 2007-07-17 Yeda Research And Development Co., Ltd. Apparatus for monitoring a system with time in space and method for diagnosing a condition of a prostate
CA2302403A1 (en) 1997-09-05 1999-03-11 Monty Krieger Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
JP2001024194A (ja) 1999-05-06 2001-01-26 Toshiba Corp 半導体装置の製造方法及び半導体装置
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US6420346B1 (en) 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
AU6174301A (en) 2000-05-19 2001-12-03 Us Health Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
JP2005503320A (ja) 2000-08-25 2005-02-03 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド ＣｐＧ−含有ポリヌクレオチドで自己免疫疾患を処置または防止する方法
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
KR20020058151A (ko) 2000-12-29 2002-07-12 박호군 집속이온빔을 이용하는 상온동작 단전자 터널링트랜지스터 제조방법
JP2005503849A (ja) 2001-06-27 2005-02-10 レイディアンシー インク． 座瘡治療
ITBO20020459A1 (it) * 2002-07-17 2004-01-19 Pei Protezioni Elaborazioni Dispositivo di copertura e protezione per macchine di impianti
RU2339647C2 (ru) 2002-08-19 2008-11-27 Астразенека Аб Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
US20040052790A1 (en) 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
US20090011974A1 (en) 2002-10-30 2009-01-08 Bocharov Alexander V Scavenger Receptor B1 (Cla-1) Targeting for the Treatment of Infection, Sepsis and Inflammation
WO2004080273A2 (en) 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating prostate cancer
WO2004080385A2 (en) 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US8017113B2 (en) * 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
WO2005025613A1 (en) 2003-03-12 2005-03-24 Rappaport Family Institute For Research In The Medical Sciences Methods of identifying biomolecular targets for diagnosis and therapy
EP1722630A4 (de) * 2004-01-20 2009-05-27 Richard F Harty Zusammensetzungen und verfahren zur behandlung von entzündungskrankheiten
JP4907117B2 (ja) * 2004-08-30 2012-03-28 ルネサスエレクトロニクス株式会社 半導体装置

Also Published As

Publication number Publication date
WO2004080273A3 (en) 2005-08-04
US7749714B2 (en) 2010-07-06
EP1601682A2 (de) 2005-12-07
US20060193863A1 (en) 2006-08-31
DE602004013554D1 (de) 2008-06-19
WO2004080273A2 (en) 2004-09-23
US8486641B2 (en) 2013-07-16
EP1601682A4 (de) 2006-06-21
US20100261210A1 (en) 2010-10-14
EP1601682B1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
GB0612649D0 (en) No title
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
HK1068411A1 (en) Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
WO2006001931A3 (en) Prouroguanylin as therapeutic and diagnostic agents
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
DE60228557D1 (de) Candida-nachweis
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE394676T1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
DE60317484D1 (de) Verfahren und vorrichtung zur vorhersage von kardiovaskulären ereignissen
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2010150254A3 (en) A method and system for the detection of cancer
TW200508605A (en) Analysis method
ATE484577T1 (de) Verfahren zur immuntherapie von tumoren
DE602004027534D1 (de) Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie
ATE408712T1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
ATE409002T1 (de) Gerät für prostatekrebsdiagnose
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
EP1724579A3 (de) Verfahren zur Diagnose von Prostatakrebs und zur Analyse von Prostatatumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties